Trial
NCT00281021
Second Line Erlotinib (Tarceva) Plus Digoxin in Non-Small Cell Lung Cancer
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
University of Louisville
Collaborators
James Graham Brown Cancer Center
Condition
Carcinoma, Non-Small Cell Lung
Intervention
Erlotinib plus Digoxin
Why stopped
Interim analysis revealed that only 1 patient had a partial response.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-03-29